Últimas noticias sobre Classover Holdings (NASDAQ:KIDZ) Bolsa

Classover Holdings Inc is an education technology company based in New York. It provides comprehensive online interactive live courses for K-12 students in the United States and around the globe. Its curriculum is designed to meet the needs of different age groups and learning levels, covering various subjects to enhance students' academic achievements and interest in exploration. The company offers both interest-oriented classes and test preparation courses for various exams and competitions. With its approach, Classover aims to transcend the boundaries of traditional education by offering students a comprehensive set of lifelong skills and capabilities, including creativity, critical thinking, and problem-solving, in an engaging and interactive environment.

Classover Holdings

San,Jose,,Ca,,Usa,-,Nov,29,,2023:,Twilio,Ads

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AAPL

ADIL

AMZN

ARDX

CNEY

EXAS

GNLN

HCTI

KIDZ

NPKI

PAPL

PLRZ

SOPA

SPHL

TEAM

TREE

TWLO

Las acciones de Twilio subieron más de un 9 % tras publicar sólidos resultados financieros trimestrales. ¿Quién más sorprendió?

Las acciones de Twilio (TWLO) suben más de un 9%; Aquí están 20 acciones que se mueven en el premercado

Classover Holdings, Inc. - Class B Common Stock

Classover Holdings Inc

KIDZTECH HLDGS LTD by KIDZTECH HLDGS LTD.

Barclays analyst Paul Kearney maintains Carter's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) with a Underweight and lowers the price target from $25 to $22.

Price Target

Analyst Ratings

Barclays Maintains Underweight on Carter's, Lowers Price Target to $22

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.
Shares of Sanmina Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) rose sharply during Tuesday's session after the company reported <a href="https://www.benzinga.com/quote/SANM/news">better-than-expected quarterly financial results.</a>
Sanmina reported quarterly earnings of $1.53 per share which beat the analyst consensus estimate of $1.42 per share. The company reported quarterly sales of $2.042 billion which beat the analyst consensus estimate of $1.983 billion.
Sanmina shares jumped 16.7% to $114.78 on Tuesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares jumped 25.3% to $17.37 after the U.S. Food and Drug Administration (FDA) recommended the removal of a voluntary hold for Elevidys.</li>
<li>Expro Group Holdings N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPRO#NYSE">XPRO</a>) gained 24.2% to $11.18 after the company reported better-than-expected second-quarter financial results and issued FY25 revenue guidance above estimates.</li>
<li>Amkor Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) rose 23% to $26.13 after the company reported better-than-expected second-quarter financial results and issued third-quarter sales guidance above estimates.</li>
<li>Polaris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) gained 21.7% to $60.26 after the company reported better-than-expected quarterly financial results.</li>
<li>Rich Sparkle Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANPA#NASDAQ">ANPA</a>) rose 21.7% to $31.69.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) gained 16.7% to $202.41 after the company reported better-than-expected second-quarter financial results and raised its FY25 guidance.</li>
<li>Chart Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) gained 15.9% to $198.99 after the company reported better-than-expected second-quarter adjusted EPS results. Additionally, the company announced that its merger agreement with Flowserve has been terminated, and Baker Hughes will acquire all the outstanding stock of Chart Industries for $210 per share.</li>
<li>SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) rose 15.5% to $24.30 after the company raised FY25 EPS and sales guidance.</li>
<li>Commvault Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) jumped 14.1% to $186.50 after the company reported better-than-expected first-quarter financial results and raised its FY26 sales guidance above estimates.</li>
<li>GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) gained 13.5% to $96.37 after the company raised FY25 sales guidance above estimates.</li>
<li>Rambus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) rose 11.3% to $71.48 after the company reported better-than-expected quarterly adjusted EPS and revenue results. Additionally, Susquehanna raised its price target on the stock from $70 to $75.</li>
<li>Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) gained 10% to $28.24 after the company reported better-than-expected quarterly financial results. Additionally, the company has announced a multi-year agreement with Indonesia&#8217;s Ministry of Health to expand image-guided therapy services to hospitals nationwide.</li>
<li>Simpson Manufacturing Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSD#NYSE">SSD</a>) rose 9.1% to $181.12 after the company reported second-quarter financial results and beat its EPS and revenue estimates.</li>
<li>TTM Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTMI#NASDAQ">TTMI</a>) gained 8.5% to $49.86.</li>
<li>CBRE Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) gained 8.2% to $158.64 after the company reported better-than-expected quarterly financial results and raised its FY25 adjusted EPS guidance above estimates.</li>
<li>Synopsys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) rose 8% to $639.84.</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) rose 7.4% to $75.33 following second-quarter results.</li>
<li>Modine Manufacturing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) gained 7% to $112.91 after the company announced a $100 million data center business investment, where it will open a new Dallas facility and expand its Grenada site.</li>
<li>Crane Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) gained 5.1% to $199.69 after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS guidance.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46679452/boeing-procter-gamble-and-3-stocks-to-watch-heading-into-tuesday">Boeing, Procter &amp; Gamble And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo via Shutterstock

Intraday Update

AMKR

ANPA

CBRE

CVLT

GTLS

INCY

RMBS

SANM

SNPS

SOFI

SRPT

TTMI

XPRO

Sanmina, Sarepta Therapeutics, Polaris, Celestica And Other Big Stocks Moving Higher On Tuesday

During Conf Call, Boeing CEO Says We've Reduced Travelled Work By 50%; Boeing CFO Says Still Expect To Be In A Position To Request Approval To Go Above 38 Per Month Max Production In The Coming Months; Expect To Shut Down 737 Shadow Factory In Q3; Expect To Close Spirit Acquisition This Year; As 737 Production Stabilizes, Co Expects To Reduce Its Buffer Inventory To Normal Levels

WIIM

Synopsys shares are trading higher in sympathy with Cadence Design Systems, which rose after raising its guidance.

<a href="https://techcrunch.com/2025/07/29/microsoft-in-talks-to-maintain-access-to-openais-tech-beyond-agi-milestone/">https://techcrunch.com/2025/07/29/microsoft-in-talks-to-maintain-access-to-openais-tech-beyond-agi-milestone/</a>

General

MSFT

'Microsoft in talks to maintain access to OpenAI's tech beyond AGI milestone'- TechCrunch

Barclays analyst Alex Scott maintains Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) with a Equal-Weight and lowers the price target from $111 to $108.

Barclays Maintains Equal-Weight on Brown & Brown, Lowers Price Target to $108

RBC Capital analyst Tom Narayan maintains Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) with a Sector Perform and raises the price target from $14 to $17.

MBLY

RBC Capital Maintains Sector Perform on Mobileye Global, Raises Price Target to $17

Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) will release earnings results for the first quarter, after the closing<a href="https://www.benzinga.com/quote/EA/earnings"> bell on Tuesday, July 29</a>.
Analysts expect the Redwood City, California-based company to report quarterly earnings at 63 cents per share, down from $1.04 per share in the year-ago period. Electronic Arts projects to report quarterly revenue at $1.23 billion, compared to $1.26 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 6, Electronic Arts reported fourth-quarter earnings of $1.58 per share, which beat the analyst consensus estimate of $1.09. Quarterly revenue clocked in at $1.8 billion, beating the consensus estimate of $1.56 billion.
Electronic Arts shares rose 0.2% to close at $151.99 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Rating</a>s page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/WBA/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Wedbush analyst Alicia Reese reiterated an Outperform rating with a price target of $210 on July 22, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Roth Capital analyst Eric Handler upgraded the stock from Neutral to Buy and boosted the price target from $175 to $185 on June 24, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Jason Bazinet maintained a Neutral rating and increased the price target from $139 to $153 on May 29, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Goldman Sachs analyst Eric Sheridan maintained a Neutral rating and raised the price target from $135 to $155 on May 8, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Baird analyst Colin Sebastian maintained an Outperform rating and increased the price target from $158 to $168 on May, 2025. This analyst has an accuracy rate of 80%.</li>
</ul>
Considering buying EA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="554" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29055545/image-443-1024x554.png" alt="" class="wp-image-1004823" style="width:591px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29055545/image-443-1024x554.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29055545/image-443-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29055545/image-443-768x415.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29055545/image-443.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46656981/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Earnings

Electronic Arts Likely To Report Lower Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Shares of solid-state battery developer QuantumScape Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) are trading sharply lower Tuesday, despite a lack of company-specific news during the session. The move comes after the company reported second-quarter financial results last Wednesday that <a href="https://www.benzinga.com/markets/earnings/25/07/46588567/quantumscape-announces-better-than-expected-q2-results-expands-collaboration-with-powerco">surpassed</a> analyst expectations.
What To Know: QuantumScape announced quarterly losses of 20 cents per share, beating the analyst consensus estimate of a 22-cent loss and improving from a 25-cent loss in the same period last year.
Alongside its earnings, the company <a href="https://s29.q4cdn.com/884415011/files/doc_financials/2025/q2/QS-SHL-Q2-2025.pdf">revealed</a> a significant expansion of its partnership with Volkswagen&#8217;s battery unit, PowerCo. Under the revised agreement, PowerCo will make additional payments of up to $131 million over the next two years if certain milestones are met.
The initial milestones, tied to payments exceeding $10 million, have already been achieved. These funds are in addition to a previously arranged $130 million due upon reaching technical progress and executing a full licensing agreement.
Operationally, QuantumScape has transitioned its baseline separator production to its next-generation &#8220;Cobra&#8221; process. The company also shipped its final &#8220;Raptor-based&#8221; B0 sample cells in the second quarter and will now ship Cobra-based B1 samples.
Financially, the company ended the quarter with $797.5 million in liquidity and <a href="https://s29.q4cdn.com/884415011/files/doc_financials/2025/q2/QS-SHL-Q2-2025.pdf">extended</a> its cash runway forecast into 2029. Management narrowed its full-year guidance for capital expenditures to between $45 million and $65 million and its adjusted EBITDA loss to a range of $250 million to $270 million.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, QS shares are trading lower by 13.3% to $9.52 Tuesday morning. The stock has a 52-week high of $15.03 and a 52-week low of $3.40.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46424452/quantumscape-qs-stock-hits-new-52-week-high-whats-going-on">QuantumScape Stock Hits New 52-Week High: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy QS Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in QuantumScape&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

QuantumScape (QS) Stock Is Sliding Tuesday: What's Going On?

On July 29, 2025, Anghami Inc., a Cayman Islands exempted company (the "Company"), issued a press release announcing a 1-for-10 reverse stock split of the Company's ordinary shares (the "Reverse Stock Split"). The Reverse Stock Split was approved by the Company's shareholders at the reconvened Extraordinary General Meeting held on July 22, 2025. The primary purpose of the Reverse Stock Split is to regain compliance with the Nasdaq Capital Market's minimum bid price requirement for continued listing. The Reverse Stock Split will not have a dilutive effect on shareholders. The reverse share split will be effected automatically, without any action required on the part of the Company's shareholders.
The reverse share split will become effective after the close of the market on August 1, 2025, and the Company's ordinary shares are expected to begin trading on a split-adjusted basis when the markets open on&nbsp;August 4, 2025 under the Company's existing trading symbol "ANGH" with the new CUSIP number G0369L200.
Upon effectiveness, every ten issued and outstanding ordinary shares will be combined into one issued and outstanding ordinary share. The par value of the ordinary shares will be proportionately increased, from $0.0001 per share to $0.001 per share. Additionally, the conversion or exercise prices of all convertible securities and warrants will be proportionately adjusted in line with the Reverse Stock Split. Shareholders will not receive fractional shares; instead, cash payments will be made in lieu of any fractional shares.

Stock Split

ANGH

ANGH Announces 1-For-10 Reverse Stock Split Effective August 1, 2025

Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst consensus but overall sales experiencing a slight year-over-year decline and missing revenue expectations.
The market&#8217;s cautious reaction underscores investor scrutiny of the company&#8217;s performance, particularly a significant drop in Gardasil vaccine sales, even as its blockbuster cancer drug Keytruda continued its strong growth trajectory.
While adjusted earnings per share (EPS) of $2.13 surpassed <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus estimates</a> of $2.04, it marked a decline from the $2.28 reported in the prior-year period. Similarly, total sales of $15.81 billion, a 2% year-over-year decrease, narrowly missed analysts&#8217; projections of $15.94 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/m-a/25/07/46317822/merck-strikes-10-billion-deal-for-verona-secures-first-in-class-copd-drug" rel="noreferrer noopener">Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug</a>
The pharmaceutical segment recorded $14.1 billion in sales, down 2% year over year, primarily due to vaccines and immunology, partially offset by <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46682141/merck-co-inc-rahway-n-j-usa-announces-second-quarter-2025-financial-results" rel="noreferrer noopener">growth in oncology and cardiology</a>.
Keytruda, an immunotherapy for cancer, delivered $7.96 billion in global sales, up 9% year-over-year, reflecting continued uptake across more cancer types and earlier treatment stages.
However, GARDASIL and GARDASIL 9, vaccines to prevent HPV-related diseases, generated $1.1 billion in sales, down 55% compared to last year. The company cited lower demand in China.
Excluding China, sales declined 3%, or 4% excluding the impact of foreign exchange, reflecting lower demand in Japan following a national catch-up immunization program, as well as the timing of public-sector purchases in certain international markets. U.S. sales increased 2% in the quarter.
The diabetes franchise, led by JANUVIA and JANUMET, remained mostly flat at around $623 million, with a slight 1% sales decrease.
Newer products, including Winrevair sales, a therapy for pulmonary arterial hypertension (a rare heart-lung condition), saw accelerated sales since its launch, reaching $336 million compared to $70 million a year ago.
CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine, saw $129 million in sales, representing continued uptake since the third-quarter 2024 launch in the U.S.
Animal Health sales increased 11% to $1.65 billion, primarily due to higher demand for Livestock products, the inclusion of sales from the Elanco aqua business acquired in July 2024, higher pricing, and improved supply.
<h2 class="wp-block-heading">Restructuring Program</h2>
Merck launched a new multiyear optimization initiative to enable the transformation of its portfolio by generating an expected $3.0 billion in annual cost savings.
The company anticipates cumulative pretax costs related to the program to be approximately $3.0 billion. For the second quarter of 2025, the company recorded charges in its GAAP results of $649 million related to this restructuring program.
Merck expects the actions under the restructuring program to result in annual cost savings of approximately $1.7 billion, which will be substantially realized by the end of 2027.
This restructuring program is part of the multiyear optimization initiative expected to achieve $3.0 billion in annual cost savings by the end of 2027.
<h2 class="wp-block-heading">Manufacturing and R&amp;D Investment</h2>
Merck continued to make long-term investments in its U.S. manufacturing and R&amp;D capabilities, including the start of construction for a $1.0 billion, 470,000-square-foot state-of-the-art biologics center in Wilmington, Delaware, which will serve as a launch and commercial production facility and the primary U.S. manufacturing site for Keytruda.
In addition, the company announced an $895 million expansion of its Animal Health manufacturing facility in De Soto, Kansas, to increase capacity for Animal Health vaccines and biologic products.
<h2 class="wp-block-heading">Guidance&nbsp;</h2>
Merck raises its fiscal 2025 adjusted earnings guidance from $8.82-$8.97&nbsp;to&nbsp;$8.87-$8.97&nbsp;compared to the consensus estimate of &nbsp;$8.90.
The company also narrowed its 2025 sales guidance from $64.1 billion-$65.6 billion to $64.3 billion-$65.3 billion versus the consensus of $65.01 billion.
The $200 million of <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44983460/mercks-q1-earnings-beat-wall-street-adjusts-2025-profit-outlook-as-tariffs-may-result-in-incremental-cost-of-200-million" rel="noreferrer noopener">costs previously included</a> in the company&#8217;s financial outlook related to the impact of tariffs is unchanged pending the outcome of additional potential government actions.
During the earnings conference call, Merck&#8217;s CEO addressed the potential impact of EU tariffs, stating that immediate implementation would have a minimal effect on 2025 results. However, the timing of these tariffs and their connection to the Section 232 investigation remain unclear.
Simultaneously, Merck revealed it will not resume Gardasil shipments to China through at least the end of this year. This decision comes as Gardasil channel inventories in China remain elevated and demand continues to be soft. Furthermore, the company anticipates that Japan will experience a &#8220;more significant headwind&#8221; in terms of growth for Gardasil in the second half of the year.
Price Action: MRK stock is trading lower by 6.19% to $78.86 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46680419/robinhood-cofounder-baiju-bhatt-offloads-42-6-million-in-stock-as-shares-soar-404-living-trust-dumps-class-a-holdings" target="_blank" rel="noreferrer noopener">Robinhood Cofounder Baiju Bhatt Offloads $42.6 Million In Stock As Shares Soar 404%—Living Trust Dumps Class A Holdings</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Guidance

Health Care

Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 10 years by 2.46% on an annualized basis producing an average annual return of 14.24%. Currently, Verisk Analytics has a market capitalization of $41.19 billion. 
Buying $1000 In VRSK: If an investor had bought $1000 of VRSK stock 10 years ago, it would be worth $3,776.86 today based on a price of $294.43 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753800313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRSK

$1000 Invested In Verisk Analytics 10 Years Ago Would Be Worth This Much Today

RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Sector Perform and lowers the price target from $50 to $45.

EXEL

RBC Capital Maintains Sector Perform on Exelixis, Lowers Price Target to $45

<a href="https://www.reuters.com/world/india/india-braces-higher-us-tariffs-eyes-broader-trade-deal-sources-say-2025-07-29/">https://www.reuters.com/world/india/india-braces-higher-us-tariffs-eyes-broader-trade-deal-sources-say-2025-07-29/</a>

INDA

'India braces for higher US tariffs, eyes broader trade deal, sources say'- Reuters

Reuters Reports Largest U.S. Rail Union Intends To Oppose Norfolk Southern And Union Pacific Merger

DRRX

DURECT shares are trading higher after announcing that Bausch Health will acquire the company for $63 million.

RBC Capital analyst Michael Carroll maintains EastGroup Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGP#NYSE">EGP</a>) with a Sector Perform and lowers the price target from $183 to $182.

RBC Capital Maintains Sector Perform on EastGroup Properties, Lowers Price Target to $182

SLRX

Salarius Pharmaceuticals shares are trading higher after the company announced it has been granted a Nasdaq extension to regain compliance with its minimum bid price requirements.

Macro Economic Events

Econ #s

Economics

Texas Services Sector Outlook For July 2.0 Vs -4.4 Prior

Dallas Fed Services Revenues For July 6.3 Vs -4.1 Prior

Press Releases

Classover Holdings Enters into $400 Million Equity Purchase Facility Agreement to Launch SOL-Based Treasury Strategy

Classover Completes Initial SOL Purchase and Enters into New Purchase Agreement to Sell up to $500 Million of Notes to Accelerate SOL Treasury Strategy

Classover Approved for Options Trading

Classover Closes Initial $11 Million Tranche of $500 Million Financing and Doubles Solana (SOL) Holdings

Fintech

Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings

Classover Acquires IP Portfolio to Accelerate AI Innovation

Classover Increases Solana (SOL) Holdings by 295%, Surpasses 50,000 SOL Tokens in Treasury Reserve

Contracts

Classover Enters Strategic Partnership with BitGo to Fast-Track Solana Treasury Initiatives

Classover Partners with Everstake to Launch "KIDZ by Everstake" Branded Validator on Solana

Classover Holds Over $11 Million in Solana, Accelerates SOL Treasury Strategy

EYEN

KIDZW

LGHL

VVPR

ATA Creativity Global - American Depositary Shares, each representing two common shares

ATA Creativity Global

Ambow Education Holding Ltd. American Depository Shares (each representing twenty (20) Class A Ordinary Shares)

Ambow Education Holding

Amesite

Bright Scholar Education Holdings Limited American Depositary Shares, each representing four Class A Ordinary Share

Bright Scholar Education

Chegg

51Talk Online Education Group American depositary shares, each representing 60 Class A ordinary shares

51 Talk Online Education

Skillful Craftsman Education Technology Limited - Ordinary Share

Skillful Craftsman

EpicQuest Education Group International Limited - Common Stock

EpicQuest Education Group

Genius Group

Golden Sun Health Technology Group Limited - Class A Ordinary Shares

Golden Sun Health Tech

Visionary Holdings

Jiade

Legacy Education

Mynd.ai

Jinxin Technology Holding Company - American Depositary Shares

Jinxin Technology Holding

Nerdy

NETCLASS TECHNOLOGY INC - Class A Ordinary Shares

Netclass Technology

Ruanyun Edai Technology Inc. - Ordinary shares

Ruanyun Edai Technology

Sunlands Technology Group American Depositary Shares, representing Class A ordinary shares

Comments

Classover Holdings

Noticias

Últimas noticias sobre Classover Holdings (NASDAQ:KIDZ) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL